Mesoblast

Mesoblast shares plunge 32% after stem-cell therapy not likely to meet target for reducing mortality due to COVID-19
Mesoblast shares plunge 32% after stem-cell therapy not likely to meet target for reducing mortality due to COVID-19
Seeking Alpha
Mesoblast
clinical trials
remestemcel-L
COVID-19
Flag link:
Mesoblast spins a PhIII cell therapy miss in heart failure as a win, highlighting positive mortality data
Mesoblast spins a PhIII cell therapy miss in heart failure as a win, highlighting positive mortality data
Endpoints
Mesoblast
FDA
clinical trials
rexlemestrocel-L
Flag link:
Novartis Inks $1.35 Billion Deal with Mesoblast for Remestemcel-L for COVID-19 ARDS
Novartis Inks $1.35 Billion Deal with Mesoblast for Remestemcel-L for COVID-19 ARDS
BioSpace
Novartis
Mesoblast
remestemcel-L
COVID-19
ARDS
clinical trials
Flag link:
Mesoblast hit by FDA rejection, request to run another trial
Mesoblast hit by FDA rejection, request to run another trial
Fierce Biotech
Mesoblast
cell therapy
clinical trials
remestemcel-L
graft vs host disease
FDA
Flag link:
Go or no go? A quiet month ahead for US approval verdicts
Go or no go? A quiet month ahead for US approval verdicts
EP Vantage
FDA
Bristol-Myers Squibb
CC-486
AML
Mallinckrodt
terlipressin
Mesoblast
Ryoncil
Flag link:
Mesoblast scores FDA committee's backing for cell therapy despite some early worries
Mesoblast scores FDA committee's backing for cell therapy despite some early worries
Fierce Pharma
Mesoblast
cell therapy
FDA
Ryoncil
graft vs host disease
Flag link:
Mesoblast faces FDA pushback over cell therapy manufacturing, clinical data: documents
Mesoblast faces FDA pushback over cell therapy manufacturing, clinical data: documents
Fierce Pharma
Mesoblast
FDA
cell therapy
drug manufacturing
Flag link:
Clinical Trials Of Mesoblast’s Stem Cell Treatment For COVID-19 Set To Begin Soon
Clinical Trials Of Mesoblast’s Stem Cell Treatment For COVID-19 Set To Begin Soon
Forbes
Mesoblast
Australia
clinical gtrials
ARDS
COVID-19
stem cells
remestemcel-L
Flag link:
3 Biotech Stocks That Soared Last Week
3 Biotech Stocks That Soared Last Week
Motley Fool
Acadia Pharmaceuticals
Nuplazid
Mesoblast
Grunenthal
MPC-06-ID
Kodiak Sciences
age-related macular degeneration
Flag link:
Mesoblast poised to file cell therapy for GVHD in US
Mesoblast poised to file cell therapy for GVHD in US
Pharmaforum
Mesoblast
stem cells
graft vs host disease
FDA
remestemcel-L
Flag link:
Mesoblast defends stem cell therapy for heart failure after trial miss
Mesoblast defends stem cell therapy for heart failure after trial miss
Fierce Biotech
Mesoblast
stem cells
clinical trials
heart failure
Flag link:
Celgene buys into Mesoblast's stem cell pipeline in regenerative med pact
Celgene buys into Mesoblast's stem cell pipeline in regenerative med pact
Fierce Biotech
Celgene
Mesoblast
regenerative medicine
stem cells
Flag link:
Biotechnology companies hunting for the keys to immortality
Biotechnology companies hunting for the keys to immortality
FT.com
Mesoblast
aging
Calico
AlloCure
stem cells
Gilead Sciences
Flag link:
Mesoblast Is No Match For Pluristem's IP And Manufacturing
Mesoblast Is No Match For Pluristem's IP And Manufacturing
Seeking Alpha
Mesoblast
stem cells
Pluristem
Flag link:
Who Will Win The Stem Cell Race?
Who Will Win The Stem Cell Race?
Seeking Alpha
stem cells
Cytori
Athersys
Thermogenesis
Mesoblast
NeoStem
Flag link:
Teva gets approval from FDA for phase 3 heart failure trial
Teva gets approval from FDA for phase 3 heart failure trial
The Fly on the Wall
Teva
Mesoblast
FDA
congestive heart failure
Mesenchymal Precursor Cells
Flag link:
Osiris exits stem cell business, sells unit to Mesoblast in $100M deal
Osiris exits stem cell business, sells unit to Mesoblast in $100M deal
Fierce Biotech
Mesoblast
Osiris
stem cells
M&A
Flag link:
Pluristem Standardizes Stem Cell Therapy, Opening Door To The Future Of Medicine
Pluristem Standardizes Stem Cell Therapy, Opening Door To The Future Of Medicine
Seeking Alpha
Pluristem
stem cells
Mesoblast
Osiris
Thermo Fisher
Flag link:
The Next Big Growth Sector In Health Care: Stem Cell Therapy
The Next Big Growth Sector In Health Care: Stem Cell Therapy
Seeking Alpha
stem cells
Advanced Cell Technology
Advanced Micro Devices
Arthersys
Neuralstem
Mesoblast
Pfizer
Teva Pharmaceuticals
Flag link:
Biotech 2012 Kickoff Party: Investor Preview
Biotech 2012 Kickoff Party: Investor Preview
TheStreet.com
Celgene
Vivus
Dendreon
Gilead
Incyte
YM BioSciences
ONYX Pharmaceuticals
Seattle Genetics
Vertex
Amarin
Biomarin
Biogen Idec
Regeneron
Merck KGaA
Human Genome Sciences
Clovis Oncology
Roche
Ariad
Immunogen
Medivation
Geron
InterMune
Indenix
Amag Pharmaceuticals
Mesoblast
Arena
MannKind
Keryx
Spectrum Pharmaceuticals
Flag link:

Pages